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The clinical presentation, diagnosis, and management of autoimmune inner ear disease are
reviewed. Recent studies indicating an autoimmune etiology and pathogenesis are discussed,
along with a comparative analysis of several promising new animal models. Further studies to
define the natural history, pathogenesis, and diagnosis ofthe disease are suggested.
INTRODUCTION
Autoimmune inner eardiseasewasfirstproposed as a distinct entitybyMcCabe in
1979 [1]. He described a series of 18 patients with sensorineural hearing loss and
hypothesized that this hearing loss was caused by an autoimmune process involving
the inner ear. His hypothesis was based on diagnostic studies and treatment
experience with the 18 patients, whose clinical patterns were not congruent with
known disease entities and appeared to merit their own category. All of these
patients responded to chronic cortisone and cyclophosphamide therapy, and thus
McCabe emphasized the importance ofrecognizing this condition, since it is one of
the few forms ofsensorineural deafness forwhich there is a treatment [1].
CLINICAL PRESENTATION
Auditory Signs and Symptoms
The typical patient is most commonly middle-aged and female, although patients
of all ages and both sexes have been described [1-5], including children as young as
eight years [5]. The patient usually presents with bilateral, asymmetric, progressive
hearing loss over a course of days to months. Some patients with a long history of
deafness in one earmaypresentwith recent unilateral hearingloss in the functioning
ear. Although as many as 21 percent of patients initially present with unilateral
hearing loss, it has been proposed that this condition may be the result of early
detection of disease which would eventually progress to bilateral loss [5]. Symptoms
may fluctuate, but the more common natural history of the disease appears to be
steadyprogression ofhearingloss [1,5]. Hearinglossmayoccur at anyfrequency, and
therefore the audiogram may be flat, downsloping, or upsloping. Localizing tests
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demonstrate the hearing loss to be sensorineural. Speech discrimination is usually
decreased but may be normal in some cases [1,6].
VestibularSigns and Symptoms
In addition to auditory symptoms, these patients may also present with vestibular
complaints. Most, but not all, patients will experience truevertigo, light-headedness,
or ataxia [1,5-7]. Vestibular testing in these patients usuallyrevealsbilateral reduced
or absent caloric responses, with reductions in caloric response paralleling the
hearing loss [6,7]. At present it is unclearwhether patients maypresentwith isolated
vestibular symptoms in the absence of auditory findings since sensorineural hearing
loss was required for establishment of the diagnosis in previous studies [1,5,6].
Prospective studies of patients presenting with vestibular symptoms alone should
determine if autoimmune inner ear disease can affect the vestibular system without
auditory system involvement.
Additional Otologic Symptoms
In addition to hearing loss and vestibular symptoms, tinnitus and aural pressure
are also frequent complaints [1,5]. A retrospective study of Hughes et al. [5] found
that approximately one-half of patients experienced aural pressure and one-third
had tinnitus, and thus these symptoms are common in this disorder. The association
of these symptoms with hearing loss and dizziness in autoimmune inner ear disease
may mimic the presentation of Meniere's disease [5,8]. In fact, it is not clear that
these two diseases represent different clinical entities, except that corticosteroid
therapy is effective in the former condition but not in the latter.
Neurologic Symptoms
Facial palsies havebeen described in twopatients [1,4], and inboth cases the facial
paralysis occurred on the same side(s) as the sensorineural hearing loss. It is unclear
if facial nerve palsy is a manifestation of the inner ear disease itself, since in one of
the two cases itwas part ofa concomitant inflammatorypolyneuropathy [4]. In either
case, cranial nerve VII palsy is uncommon but can occur in association with this
disorder.
Association with OtherAutoimmune Disorders
Patients with autoimmune inner ear disease will frequently have or subsequently
develop other diseases thought to be autoimmune in origin. These other diseases
include Cogan's syndrome, chroniculcerativecolitis, rheumatoidarthritis, polyarteri-
tis nodosa, carotidynia, temporal arteritis, systemic lupus erythematosus, Hashimo-
to's thyroiditis, polymyositis, juvenile rheumatoid arthritis, and systemic vasculitis
[1,5,9-12]. Hughes et al. [5] retrospectively studied 52 patients with autoimmune
inner ear disease and demonstrated that 29 percent of them had one of these other




Several lines of evidence indicate that the etiology of autoimmune inner ear
disease is immune-mediated. First, sera from these patients frequently contain
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circulating immune complexes, suggesting that inner ear injury may occur via an
immune complex-mediated (Type III) hypersensitivity reaction [2-4]. This type of
reaction can be initiated by the formation of immune complexes in autoimmune
disease or persistent infection (see [13] for review). Second, there is a nearly
universal response of the disease to systemic corticosteroid and cytotoxic therapy
[1,2,4,6,12,14]. These therapies are known to be effective in other diseases of
inflammatory or autoimmune origin, and their efficacy in treating autoimmune inner
ear disease suggests that the pathogenesis of this disease is also immune-mediated.
Third, temporal bone pathology in one specimen from a patient revealed vasculitis,
"ghosts" of blood vessels, and granulomatous tissue, all of which indicate immune
injury [1]. Examination of more specimens is required, however, before it can be
concluded that this is a uniform finding indicative of immune injury to the inner ear.
Fourth, the frequent association of this disease with other known or suspected
autoimmune diseases indicates that it is an autoimmune process itselfor it is a result
of these other systemic autoimmune processes [5,15]. In summary, the current facts
suggest that tissue injury is mediatedby immune mechanisms.
Despite these observations, autoimmune inner ear disease may be a misnomer,
since there is no definitive evidence implicating autoimmunity in this disease. At
least some tissue injury may be attributed to the deposition of circulating immune
complexes in inner ear tissue, resulting in local inflammation and tissue damage, but
it should be noted that immune-mediated tissue injury may occur via a combination
of different mechanisms (see [13] for review). Immediate (Type I) or delayed (Type
IV) hypersensitivitycould alsopotentially cause inner ear tissue injury similar to that
which is observed in autoimmune inner ear disease, although there is currently no
evidence to suggest this process. In contrast, there is substantial evidence that inner
ear injury is at least partially mediated by an antibody-dependent cytotoxicity (Type
II hypersensitivity) mechanism. In Type II hypersensitivity, antibodies bind to
antigen(s) present oncells,leading tophagocytosis, killercellactivity, orcomplement-
mediated lysis. Elucidation of the inner ear antigenic targets of such antibodies
wouldprovide compellingevidence forType 11-mediated inner ear injury, andwould
definitively establish autoimmune inner ear disease as a bona fide primary autoim-
mune process.
Evidencefor anAutoimmuneEtiology
Laboratory studies of peripheral blood lymphocytes and antibodies from patients
with this disorder have provided the most convincing argument that the disease has
an autoimmune etiology. In contrast to routine screening tests, assays of antigen-
specific immune responses to pooled inner ear antigen preparations have provided
the best evidence for an autoimmune process in this disease.
Earlierinvestigations used the enzyme-linked immunosorbent assay (ELISA) and
indirect immunofluorescence to detect humoral immunity to inner ear antigens
[6,8,10,16-18]. The ELISA is a solid-phase assay for the measurement of serum
levels of antibodies against crude inner ear antigen preparations, whereas indirect
immunofluorescence detects the direct binding of serum antibodies to thin sections
ofbovine or guinea pig cochlear tissue. Only some ofthe studies detected antibodies
to inner ear antigens [16-18], although the discrepancies most likely arise from
differences in experimental technique.
These findings were extended by a recent study of Harris and Sharp, who used
two-dimensional gel electrophoresis and immunoblot analyses to define, at the
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molecular level, the autoantigen(s) recognized by anti-inner ear antibodies [19].
They found that 19 of 54 sera from patients with autoimmune inner ear disease
selectively bound an antigen (or antigens) migrating as a single or double band at
68,000 molecular weight. Whereas only one of 14 normal human sera bound this
antigen, sera from four of five control patients with ulcerative colitis recognized this
antigen (or antigens). Of note is the fact that patients with ulcerative colitis have
been shown to be predisposed toward developing sensorineural hearing loss [9,11]. It
is therefore unclear if the presence of this antibody (or antibodies) is specific for
patients with inner ear disease or if it is found nonspecifically in autoimmune or
inflammatory disorders. It will be interesting to determine if the 68 kilodalton (kDa)
antigen (or antigens) is unique to the inner ear or if it is ubiquitous among different
tissues, since the former finding would imply a specific (Type II) autoimmune process
directed against the inner ear.
The concept of humoral autoimmune response directed against inner ear antigens
is further supported by a series of studies which demonstrated that the inner ear has
the anatomic components to mount an immune response [20,21]. It has been shown
that the endolymphatic sac provides an immunologic role for the inner ear in a
manner similar to that of gut-associated lymphoid tissue [22-24]. Thus the inner ear
is not an immunologically privileged organ and appears to have the potential to
generate a primary autoimmune process.
Several investigations have also demonstrated cellular immune responses to inner
ear antigens, further supporting a role for autoimmunity in disease pathogenesis
[1,25]. These studies employed the lymphocyte migration inhibition assay and the
lymphocyte transformation test, both of which measure the response of the patient's
lymphocytes to pooled inner ear antigen preparations [26]. These preparations are
crude extracts of inner ear membranes from people without autoimmune inner ear
disease. The lymphocyte transformation test measures the difference in proliferation
of the patient's lymphocytes in the presence and absence of these antigens. The
measured difference in proliferation is compared to that of lymphocytes from normal
human control subjects. The lymphocyte migration inhibition assay is an analogous
assay, measuring lymphocyte migration in the presence or absence of inner ear
antigens. A significant difference between the responses of the patient and normal
control lymphocytes is considered a positive response in either assay [26].
Several studies have now shown that lymphocytes from patients with autoimmune
inner ear disease respond positively in these assays using inner ear membrane
preparations [1,5,6,8,10,25], indicating the existence of an inner ear antigen-specific
cellular immune response in these patients. Not all patients, however, will have
positive lymphocyte transformation tests or migration inhibition assays, and some
patients without autoimmune inner ear disease will respond positively in these assays
[1,25]. Thus these assays are not completely specific nor sensitive for autoimmune
inner ear disease, and a cellular autoimmune response may not be a uniform feature
in these patients. Alternatively, the limited sensitivity and specificity ofthe assay may
be a reflection of the assay itself, and not of the actual immune response itself.
Indeed, other groups have been unable to demonstrate a significant cellular immune
response using such assays [12,16]. Further studies with more purified antigen
preparations might increase the sensitivity and specificity of these assays, providing
more uniform and reliable results.
Despite the evidence demonstrating cellular and humoral autoimmune responses
directed against inner ear tissue, there are still basic questions regarding the
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relationship of the immune lesion to disease manifestations in these patients. The
frequent association of the disease with other autoimmune diseases is especially
interesting, as it may indicate a possible common denominator between them. For
example, some individuals may be genetically predisposed to develop autoimmunity,
and such individuals who develop autoimmune inner ear disease might be prone
toward developing autoimmunity against other tissues as well. Alternatively, autoim-
mune inner ear disease may be a final common pathway for inner ear disease in a
host of different immune-mediated disorders. For instance, if inner ear injury is
caused by circulating immune complexes, any systemic inflammatory or infectious
disorder which produces circulating immune complexes could potentially result in
inner ear tissue injury. Therefore it is possible that autoimmune inner ear disease
does not truly represent a distinct disease entity, but rather is a syndrome with
multiple different etiologies. Finally, it is unknown whether the observed immune
response actually causes tissue injury or if it is merely an epiphenomenon. The initial
inner ear injury may not be immune-mediated, and the observed anti-inner ear
immunity is a response to the injury but not its cause. In summary, further
investigations are required to define the immune lesion (or lesions) and its relation-
ship to inner ear damage and disease manifestations.
Animal Models ofDisease
Because of the difficulties encountered using human subjects to study the disease,
several investigators have created animal models for autoimmune inner ear disease.
The most promising models involve the immunization of rodents with inner ear
antigens, and have yielded somewhat conflicting results.
For example, Yoo et al. [27] immunized rats with native bovine typeII collagen, a
major structural protein of the inner ear [28-30], and induced sensorineural hearing
loss in these animals. The immunized animals had high levels of antibodies to native
typeII collagen, and affected animals had histopathologic changes consisting of
cochlear nerve degeneration and perineural vasculitis [27]. A subsequent study
further characterized the temporal bone lesions in this model. These lesions con-
sisted of mild atrophy of the organ of Corti and spiral ganglion degeneration,
vestibular dysfunction with vacuolar degeneration of the crista ampullaris, otospon-
giosis-like lesions in the tympanic annules, cochlear vasculitis, and eustachian tube
disease [31]. Of note is the fact that both cellular and humoral immune responses to
typeII collagen were demonstrated in this study. Moreover, a subsequent study
demonstrated that antibodies to typeII collagen were present in the inner ear
perilymph [32]; however, comparison of the described histopathologic changes to
those which occur in human disease is difficult, owing to the lack of human temporal
bone pathology specimens.
Harris performed similar experiments in which he studied the effects of typeII
collagen autoimmunity in the well-established Wistar-Furth rat model of typeII
collagen autoimmune arthritis [33]. No hearing loss was found in the immunized
animals, except for four animals that had spontaneous, purulent otitis media. All
immunized animals showed very significant serum and perilymph antibody titers to
typeII collagen. No morphological abnormalities of the external, middle, or inner
ears could be identified, however, in contrast to Yoo's observation that typeII
collagen autoimmunity results in ear disease [27,31].
In order to characterize further the role of antibodies to type II collagen in inner
ear disease, Cruz et al. used guinea pigs to compare cochlear alterations produced by
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induction of anti-type11 collagen antibodies with alterations produced by passive
transfer of anticochlear antibodies [34]. They found loss of nuclei in the spiral
ganglia in both experimental groups, but significant changes in the brainstem
auditory evoked response were notpresent. They concluded that antibodies to type
II collagen mayplay an important role in human autoimmune sensorineural hearing
loss, but other cochlear antigens may be important [34].
Harrisinvestigated the role of other cochlear antigens by immunizing guinea pigs
with fresh bovine cochlear antigens, which produced a significant hearing loss
compared to acontrolgroup ofanimals[35]. Thepresence ofanticochlear antibodies
wasuniformlydetected intheexperimentalgroup ofanimals, and 32 percent ofthose
ears tested had significant hearing losses. Histologic examination revealed spiral
ganglion cell degeneration, perivascular infiltration by plasma cells, edema, and
hemorrhage. Some animals showed unilateral hearing losses, whereas others had
bilateral losses ofvarying extent. Western blot analyses demonstrated an antibody
that was present in the hearing loss animals, but not in those immunized, in which
hearing was maintained. Although the particular autoantigen (or autoantigens) was
not identified, the results suggest that a specific anticochlear autoantibody was
responsible for the hearing loss [35]. Subsequent work has indicated that the
immunodominant autoantigen is not typeII collagen [36], supporting the results of
Harris's previous study [33] and that ofCruz et al. [34].
Soliman hasconstructed a similarmodel, inwhichguinea pigs are immunized with
a crude inner ear antigen preparation [37]. These animals develop sensorineural
hearing losses and specific anti-inner ear antibodies whose immunofluorescence
patterns are similar to those of sera of human patients. In addition, these animals
have innerearhistopathologicchangeswhichclosely resemble those discussed above
[35].
Thediscrepancies between the studies ofHarris et al. [33] and those of Yoo et al.
[27,31] may arise from differences in the animal strains used and quantitative or
qualitative differences in the immune response and its subsequent effects on tissue
injury. Moreover, the animal models may represent somewhat different disease
entities, as Yoo's typeII collagen autoimmunity model appears to approximate
Meniere's disease moreclosely [38-40]. Furthermore, Yoo et al. have demonstrated
increased levels of antibodies to type II collagen in the sera of patients with
otosclerosis and Meniere's disease [41], indicating that this model more closely
approximates these latter two conditions than it does autoimmune inner ear disease
itself. Takentogether, all ofthese studies show that cochlear antigens are important
in the autoimmune response and disease pathogenesis of these animals. The role of
type II collagen in inner ear disease is presently unclear, but definition of the
cochlearautoantigen(s) andhistopathologicchanges in human disease should clarify
this issue. Such studies should also identify which animal models most closely
approximate the human disease, and the extent to which results obtained with the
animal models can be extrapolated to human disease.
DIAGNOSIS
There are no uniform criteria for the diagnosis of autoimmune inner ear disease.
Obtaining inner ear tissuebiopsies is not feasible in human patients, and, as a result,
thediagnosis isnotmadehistopathologically. The clinical picture, laboratory studies,
andresponse to treatment are currently the cornerstones of diagnosis. The individ-
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ual diagnostic criteria are each nonspecific and can be met in a number of other
disorders, but together they can be used to identify autoimmune inner ear disease
with a moderate degree ofsuccess.
ClinicalDiagnosis
As described above, the disease is a progressive, bilateral, asymmetric, sensorineu-
ral hearing loss. Although sensorineural origin and asymmetry are the only features
which appear to be uniformly present among all patients, the onset and time course
ofdisease are especially useful in diagnosis. Specifically, its progression over days to
months serves to distinguish it from several other diagnostic possibilities. For
example, chronic progressive deafness of adolescence, presbycusis, or recessive
progressive hereditary deafness all follow a slower time course [1]. In addition,
recessive progressive hereditary deafness can be distinguished on the basis of a
positive family history, whereas autoimmune inner ear disease does not appear to
have a hereditary component.
Additional findings such as vestibular symptoms, aural pressure, and tinnitus are
frequentlypresentbut are neither sensitive norspecific for the disease [7]. Therefore
they have limited utility in establishing the diagnosis.
The clinical history is also essential for ruling out other causes of sensorineural
hearing loss such as noise-induced hearing loss, luetic hearing loss, head trauma,
perilymphatic leak, or drug toxicity. Laboratory studies should include fluorescent
treponemal antibody (FTA) testing to rule out luetic hearing loss, ifit is indicated by
theclinical history. Radiologic studies maybe required to evaluate the possibilityofa
tumor causing the hearing loss. The clinical diagnosis of autoimmune inner ear
disease thus remains a diagnosis ofexclusion rather than ofpositive findings.
Patients presenting with autoimmune inner ear disease may frequently be identi-
fied by the presence of concomitant autoimmune diseases such as systemic lupus
erythematosus, Cogan's syndrome, and others [1,5,10,12]. The co-occurrence of
these with inner ear disease is not diagnostic for autoimmune inner ear disease, but
should prompt the clinician to proceedwith an immunological laboratoryworkup.
Finally, autoimmune inner ear disease can mimic Meniere's disease in its clinical
presentation [6,8]. Such patients should undergo evaluation for autoimmune inner
ear disease, including immunological laboratory testing, since treatments for the two
conditions are different. Patientswho havefailed conventionaltherapyforMeniere's
disease should probably be started on a trial of corticosteroids, regardless of the
results ofimmunological tests [15].
The diagnosis of autoimmune inner ear disease cannot be made on clinical
grounds alone, since the disease is heterogeneous in its presentation and its features
arenonspecific. The clinicalfindings are neithersensitive norspecificfordetection of
this disease and should serve only toidentify those patientswho do not fit neatly into
other disease categories and thus merit further evaluation. This evaluation relies on
immunological laboratory studies, with the goal of empirically identifying patients
whowill benefit from systemic corticosteroid therapy.
Laboratory Diagnostic Evaluation
None of the laboratory evaluations for autoimmune inner ear disease is 100
percent sensitive or specific, but they are generally useful prognostic indicators for
response to corticosteroid therapy [15,25]. Laboratory tests for the identification of
23ANDREW J. GRIFFITH
TABLE 1
Clinical Analyses for Autoimmunity
(adapted from [3])








Complexes containing IgG, IgM, IgA
Complement system








the disease can be classified as either antigen-specific or antigen-nonspecific tests of
immune function. Antigen-nonspecific tests include the erythrocyte sedimentation
rate, serum immunoglobulin levels, rheumatoid factor, autoantibodies, circulating
immune complexes, and complement levels. Veldman suggests the laboratorystudies
outlined in Table 1 to evaluate the presence ofautoimmunity [3,15]. At least some of
these tests will usually be abnormal in autoimmune inner ear disease, and their
availability to most clinicians makes them useful for routine screening [15].
In contrast, antigen-specific tests such as the lymphocyte transformation test, the
migration inhibition assay, and indirect immunofluorescence and Western blot
analyses of cochlear antigens are available only in a limited number of research
laboratories. These tests appear to be useful in identifying those patients who will
respond to steroid therapy. Although their sensitivity and specificity are high, these
are not 100 percent [17,25]. Hughes et al. reported that 79 percent of patients with
positive lymphocyte transformation test results responded to corticosteroid therapy
[25]. Positive results in these assays in the context ofthe appropriate clinical picture
thus predict a beneficial response to corticosteroid treatment, and such treatment
should be instituted in these patients. In patients with negative test results who
otherwise appear to fit the clinical picture of autoimmune inner ear disease, the
decision to start steroid therapy is more difficult, given the lack of quantitative
objective data. Some patients with negative laboratory test results will, however,
respond to corticosteroid therapy [12,17], and, given the possible deleterious out-
come, a trial ofcorticosteroids iswarranted in such patients [1,25].
Response to Corticosteroid Therapy
Apositive response tocorticosteroid therapyisthe third criterion forthe diagnosis
of autoimmune inner ear disease. It consists of a test of treatment with either
corticosteroids [6] or corticosteroids and cyclophosphamide [1,42]. A reversal or
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stabilization ofthe hearing loss with corticosteroid treatment confirms the presump-
tive diagnosis.
MANAGEMENT
Treatment guidelines for autoimmune inner ear disease remain controversial;
however, current therapeutic regimens include systemic corticosteroids, cytotoxic
agents such ascyclophosphamide, and plasmapheresis. The former two therapies are
suppressors ofimmune function, and the rationale for their use is that tissue injury is
immune-mediated and immunosuppression should thus decrease tissue damage.
Similarly, the rationale for plasmapheresis is that removal ofcirculating acute-phase
immune complexes might decrease inner ear tissue injury. This therapy is based on
the assumption that at least some tissue injury is caused by immune complex
deposition.
Systemic Corticosteroid Therapy
At present, many but not all patients respond to short-term, high-dose corticoste-
roids followed by maintenance doses over several months. Patients should be
followedboth clinically and audiometrically to assess the effect oftherapy. Hughes et
al. recommend a trial of prednisone at 1 mg/kg/day by mouth for one month if
steroids are not contraindicated [5]. They believe this dosage and duration are
adequate for a trial oftherapy, and maintenance therapy of 10 mg orally every other
day can be continued for many months if required to maintain hearing. These
authors stress that corticosteroid treatment, even at maintenance levels, should not
be discontinued prematurely ifthe patient fails to show an initial dramatic response.
In addition, treatment delayed up to several months still can help some patients to
recover useful hearing. Finally, a dramatic initial response is not always maintained
even if the immune process is inactive [5]. Hughes treats such patients with
second-course, high-dose corticosteroids, but offers cytotoxic drugs to them and to
those patients whofail to respond initially to corticosteroids. Their initial experience
with this regimen was improved hearing in four patients, stabilized hearing in four
patients, and decreased hearing in one patient [6]. All except one patient regained
normal or near-normal hearing levels or levels amenable to a hearing aid [6]. Similar
results have been reported by Moscicki et al., who found that patients frequently
required a second course of high-dose corticosteroids for adequate remission of
disease [12]. Several other groups have also found that corticosteroid therapy is
effective in reversing, or at least stabilizing, hearing loss [2,14].
Concurrent Cytotoxic and Systemic Corticosteroid Therapy
McCabe has emphasized that the mainstay of therapy is cyclophosphamide, not
corticosteroids [42]. He contends that corticosteroids alone are not adequate treat-
ment, or even a test for treatment, because many patients who actually have the
disease will be missed and their hearing will irretrievably be lost. Patients who
progress to total deafness gain no benefit from treatment once reaching that point.
On the other hand, patients who have severe loss improve to moderate loss,
moderate losses improve to a mild loss, and mild losses improve to normal hearing.
He stresses that the most important gain in patients with severe loss is improvement
in discrimination scores, enabling them to be rehabilitated with hearing aids (e.g.,
improvements of40 percent to 50 percent in discrimination).
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McCabe's test oftreatment is the administration ofcyclophosphamide, 2mg/kgby
mouth every 12 hours, and prednisolone, 30 mg by mouth every other day, for three
weeks [42]. If there is any significant improvement in speech discrimination or pure
tone audiometry, full treatment is commenced. Full treatment consists of continua-
tion of the same drugs and levels for three months, at which time the cyclophospha-
mide is stopped and the prednisolone continued for two weeks. If the hearing is at
least stabilized, prednisolone is tapered over two weeks, but if hearing drops before
or after the prednisolone has been tapered, full treatment is reinstituted for an
additional three months. The same procedure is then repeated if necessary. Some
patients require treatment for as many as eight such cycles (twoyears) but no longer
than that [42].
The cyclophosphamide is safewhengiven atthe 2mg/kg dose ifthe patient'swhite
blood count is monitored carefully. The count should be takenweekly, and ifit drops
below 5,000 cells per cubic mm, the drug should be stopped until it goes back above
5,000. This condition rarely happens because of the concomitant prednisolone,
which promotes a leukocytosis. McCabe sees this leukocytosis as the chief role of
prednisolone in treatment, not its immunosuppressant activity [42].
It is not clearwhat the optimal treatment protocol is forpatientswith autoimmune
inner ear disease. McCabe's approach probably treats more patients successfully
than would be possible with the use ofsteroids alone, but quantitative data have not
yet been published to support this concept. Cyclophosphamide therapy is, however,
more toxic than corticosteroid treatment. Rigorous comparison of the treatment
modalities is currently impossible, though, since detailed treatment regimens and
results have not been published. Prospective studies are needed to provide rational
guidelines for the treatment ofthese patients.
Plasmapheresis
This therapy has theoretical benefits but practical limitations. Treatment results
with plasmapheresis are largely anecdotal, and its utility is unclear due to the lack of
controlled prospective studies. In one uncontrolled study, six of eight patients
receiving plasmapheresis therapy had improved auditory function [43]. Moreover,
three ofthe patients no longer required immunosuppressant medication to maintain
their hearing. Plasmapheresis is expensive, however, with one month of outpatient
treatments costing approximately $5,000. Insurance coverage of this treatment for
autoimmune inner ear disease is not guaranteed and is an important consideration
when deciding whether to start treatment. Hughes et al. thus feel that the primary
indication for plasmapheresis is progressive autoimmune hearing loss which has not
responded to sequential or concurrent cytotoxic drug therapy [6]. In summary,
plasmapheresis remains an expensive experimental therapy ofunknown benefit, and
controlled studies are required to determine its role in treating autoimmune inner
eardisease.
PROBLEMS AND FUTURE DIRECTIONS
Much remains to be learned about the natural history of autoimmune inner ear
disease, as well as its incidence and prevalence. This situation exists largely because
the methods currently used to define and diagnose the disease are inadequate. Past
studies have been largely retrospective, and there is a great need for controlled
prospective investigations to define more accurately the patient population and the
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clinical manifestations ofthe disease. Current andfuture studies should also include:
(1) The examination of human temporal bone specimens in order to elucidate the
etiology and histopathogenesis ofinner ear tissue injury: such studies would also aid
in the interpretation of animal models, where histopathologic data are easily
obtained but cannot yet be extrapolated to the human disease process until similar
data are also available for human patients. (2) Definition of the inner ear autoanti-
gens recognized by antibodies in the sera of human patients: this finding would
establish the disorder as having an autoimmune component, and the purified
autoantigens could be used to improve the sensitivity and specificity of laboratory
tests currently used to identify the disease. (3) Prospective trials to compare the
treatment results ofcorticosteroid, cytotoxic, and plasmapheresis therapies: not only
would such trials aid clinicians in treatment decisions, but they would also be useful
in identifying patients, since response to immunosuppressive therapy is currently a
diagnostic criterion. These studies should thus improve our understanding and
treatment of autoimmune inner ear disease, as well as provide new insight into the
basic biology and immunology ofthe inner ear.
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